Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

Studies on the distribution and radioimmunoimaging of 99m Tc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts

Studies on the Distribution and Radioimmunoimaging of 99mTc-Labeled 5-Fluorouracil Loaded Immunological Nanoparticles in Tissues and Human Gastric Carcinoma Xenografts

[Biodistribution of (99m)Tc-labeled anti-VEGF mAb 5-FU loaded polylactic acid nanoparticles in human gastric carcinoma xenografts].

Study of the Anti-Tumor Effect of Anti-Vascular Endothelial Growth Factor McAb 5-Fluorouracil Loaded Polylactic Acid Nanoparticles

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Study of Targeted and Controlled Release of 5-Fluorouracil-loaded PLA Nanoparticles and Microspheres on Treatment of Gastric Tumor

Effects of Intratumoral Injection of 5-Fluorouracil-loaded Polyactic Acid Sustained Release Preparation on Gastric Cancer

The anti VEGF monoclonal antibody conjugated with nanometer particle of 5-FU

SM5-1-Conjugated PLA Nanoparticles Loaded with 5-Fluorouracil for Targeted Hepatocellular Carcinoma Imaging and Therapy

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )

Combined Therapeutic Effects of 131I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer.

Preliminary radioimmunoimaging and biodistribution of ¹³¹iodine-labeled single-chain antibody fragment against progastrin-releasing peptide(₃₁₋₉₈) in small cell lung cancer xenografts.

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Inhibitory effect 131I-antiAFP McAb-DOX-BSA nanoparticles on hepatocellular carcinoma bearing nude mice

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

The experimental study of radioimmunoimaging and radioimmunotherapy using ~(131)I-labeled anti-progastrin-releasing peptide_((31-98)) monoclonal antibody E-B_5

Quality Control, Metabolism Analysis And Micro-Pet Imaging Of Cu-64-Nota-Trastuzumab In Gastric Cancer Patient-Derived Xenograft Mouse Model

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

EXPERIMENTAL STUDY OF RADIOIMMUNOIMAGING WITH~(99m)Tc LABELING F(ab’)2 FRAGMENT

Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors